SK bioscience Co.,Ltd.
Research SK bioscience Co.,Ltd. (302440.KS) on Bullrun: market cap KRW 2.85T. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker302440.KS
- ExchangeKS
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 2.85T
- Financial periodQ2 2026
- RevenueKRW 155.71B
- Net income-KRW 17.89B
- Free cash flow-KRW 64.26B
- Gross margin26.7%
Valuation Snapshot
latest market cap is KRW 2.85T.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 2.85T | n/a | n/a | n/a |
Dividend history
About SK bioscience Co.,Ltd.
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children.
ETFs that hold SK bioscience Co.,Ltd.
US-listed ETFs
SK bioscience Co.,Ltd. is held by 27 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Core MSCI Emerging Markets ETF (IEMG) | <0.01% | 0.09% |
| Vanguard FTSE Developed Markets Index Fund ETF Shares (VEA) | <0.01% | 0.03% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Schwab International Equity ETF (SCHF) | <0.01% | 0.03% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| iShares Core MSCI Total International Stock ETF (IXUS) | <0.01% | 0.07% |
| Avantis Emerging Markets Equity ETF (AVEM) | <0.01% | 0.33% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SK bioscience Co.,Ltd.'s market cap?
SK bioscience Co.,Ltd.'s market capitalization is KRW 2.85T.
What does SK bioscience Co.,Ltd. do?
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children.